Silibinin nephroprotective effects in renal ischemia reperfusion injury in rats via regulation of Notch-1
AuthorsManar H. Mohammed, Fadhel J. Rizij2
JournalWiadomości Lekarskie Medical Advances
Date2025-11-01
AbstractAim: To evaluate nephroprotective effects of Silibinin in renal ischemia -reperfusion injury in rats by regulation of Notch-1 and Jagged-1.
Materials and Methods: 28 male Wistar albino rats were randomly divided into four groups, (seven rats / group): sham group (laparotomy only), control group
(ischemia for 30 min / 2 hrs reperfusion), DMSO vehicle group (rats were injected intraperitoneally with 10% DMSO 1 hour before ischemia, then ischemia for
30 min / 2 hrs reperfusion, Silibinin treatment group (rats were injected with Silibinin (60 mg/kg) intraperitoneally 1 hour before ischemia, then “ischemia for
30 min / 2 hrs reperfusion. The kidneys were harvested after 2 hours of reperfusion for assessment of kidney injury molecule-1 (KIM-1), interleukin 1 β (IL-1β),
TNF-α, F2-Isoprostane, and glutathione (GSH) by ELISA technique; Notch-1 and Jagged-1 mRNA levels were assessed by reverse transcription-polymerase chain
reaction (RT-PCR), BAX and Bcl2 protein expression were assessed by immunohistochemistry (IHC).
Results: Silibinin demonstrated considerable amelioration of renal ischemia reperfusion injury as evidenced by the significant reduction of KIM-1, IL-1β, TNF
α, F2-Isoprostane, in rat kidneys pretreated with Silibinin, GSH level was significantly elevated in rat kidneys pretreated with silibinin. Furthermore silibinin
pretreatment significantly reduced Notch-1 and Jagged-1 mRNA expression after renal ischemia reperfusion.
Conclusions: Silibinin offers protection against renal ischemia reperfusion injury due to its antioxidant, anti-inflammatory, and anti-apoptotic effects, those
effects are associated with the downregulation of Notch-1 and its ligand, Jagged-
MYRICETIN AMELIORATES BRAIN DAMAGE INDUCES BY CEREBRAL ISCHEMIA-REPERFUSION INJURY IN RATS
AuthorsManar Hameed Mohammed, Fadhaa Abdulameer Ghafil
Wadhah Mahbuba
Laith M Abbas Al-Huseini
Maysaa Ali Abdul Khaleq
Zina Zwaini
Najah R Hadi
Journal Asian Journal of Pharmaceutics (AJp
AbstractBackground: Interruption of blood flow may result in considerable tissue damage via ischemia/ reperfusion injury induced oxidative stress in brain tissues. The present study aimed to investigate the effects of myricetin treatment in rats cerebral I/R injury. Material and Methods: The study was carried out on 36 Wistar-albino rats, divided into four groups including Sham group, I/R group, I/R+(control-vehicle DMSO) and I/R+ myricetin 50 mg/kg intraperitoneally 1 hour before induction of ischemia. Measurement of brain tissue IL-1β, ICAM- 1, caspase-3, Notch 1 and jagged 1 was done after one hour of reperfusion with assessment of the brain infarcted area and histopathological analysis. Results: Myricetin attenuates the cerebral I/R injury induced increase in inflammatory cytokine (IL-1β), adhesion molecule (ICAM-1) and proapoptotic enzyme (caspase-3). Additionally, it reduces the size of infarcted area and histopathological damage. However, such protective effect was not found to be mediated by Notch 1 pathway because myricetin treatment didn’t show changes in the increased levels of Notch 1 and Jagged 1 seen in brain with I/R injury. Conclusions: Myricetin has a neurocytoprotective effect against cerebral I/R injury which is manifested as anti-inflammatory anti-apoptotic preserving cell structure and viability, nevertheless this effect is not mediated through Notch 1 pathway.
USE OF INFLIXIMAB TO ATTENUATE CEREBRAL
APOPTOSIS INDUCED BY CEREBRAL ISCHEMIA/REPERFUSION
IN MALE RATS
AuthorsSaif M. Hassan1, , Manar Hameed Mohammed2
, Mahmood J. Jawad1
, Ashwaq Najemaldeen Abbas3
JournalWiadomości Lekarskie Medical Advances
Date2023-02-02
AbstractThe aim: The purpose of the research was to study the role of infliximab global cerebral ischemia-reperfusion injury.
Materials and methods: The rats were split into five groups: Sham group; Control group: occlusion of the common carotid artery for 60 minutes, and subsequently reperfusion for an hour without receiving any medication; Vehicle group: as the control group, but 72 hours before to the ischemia, they were given
the medication 0.9 NaCl intraperitoneally (i.p); Treated group-1: as the control group, plus 3 mg/kg of IFX intraperitoneally (i.p) 72 hours prior to ischemia;
Treated group-2: as the control group, plus 7 mg/kg of IFX intraperitoneally (i.p) 72 hours prior to ischemia.
Results: Pre-treatment with IFX significantly reduced the percentage of infarct area, but in the IFX (7 mg/kg) group, the infarct area was smaller than at the
low dose. The ischemia group had a significant elevated of TNF-α and caspase-3 while a significant lowered in CAT and SOD levels. The pre-treatment with IFX,
the TNF-α and caspase-3 levels lowered significantly, furthermore, significantly increased CAT and SOD levels activity (P≤0.05) as compared with IR group.
Among effective groups, I/R+IFX (7mg/kg) group more effective in lowering TNF-α and caspase than I/R+IFX (3mg/kg) group.
Conclusions: Infliximab has neuroprotective effective due to its powerful TNF-α blocker and limit ROS release and cell death signaling which protects the
neurons from injury during cerebral ischemia reperfusion.
Role of dimethyl fumarate (Nrf2 activator) in reducing of ciprofloxacin-induced hepatotoxicity in rats via the Nrf2/Ho-1 pathway
AuthorsMahmood Jawad1, , Karam Al-Akkam2
, Manar Mohammed3
, Saif M. Hassan
JournalWiadomości Lekarskie Medical Advances
Date2023-05-01
AbstractABSTRACT
The aim: The present study aims to study the effect of DMF on ciprofloxacin-induced liver damage as assessed by liver function and liver pathology and to
study this effect if it is thought to activate the Nrf2 antioxidant defense mechanism.
Materials and methods: G1 (control), G2 (ciprofloxacin group), G3 and G4 (two DMF groups rats treated with DMF 50mg and 100mg), and G5 and G6 (two
DMF groups rats treated with DMF 50mg and 100mg) (two ciprofloxacin Plus DMF at 50 mg and 100 mg). The tests included study of liver function, Nrf2
analysis, and anti-oxidant enzyme analysis.
Results: The serum blood Nrf2, HO-1, and tissue anti-oxidant enzymes all increased after ciprofloxacin treatment. The serum levels of Nrf2 and HO-1 were higher
in the ciprofloxacin plus DMF groups, but anti-oxidant enzymes were lower. DMF increased Nrf2 expression in rats when ciprofloxacin caused hepatotoxicity.
Conclusions: DMF lowers experimental hepatotoxicity in vivo. This effect is thought to activate the Nrf2 antioxidant defense mechanism
Role of dimethyl fumarate (Nrf2 activator) in reducing of ciprofloxacin-induced hepatotoxicity in rats via the Nrf2/Ho-1 pathway
AuthorsMahmood Jawad1, , Karam Al-Akkam2
, Manar Mohammed3
, Saif M. Hassan
JournalWiadomości Lekarskie Medical Advances
Date2023-05-01
AbstractABSTRACT
The aim: The present study aims to study the effect of DMF on ciprofloxacin-induced liver damage as assessed by liver function and liver pathology and to
study this effect if it is thought to activate the Nrf2 antioxidant defense mechanism.
Materials and methods: G1 (control), G2 (ciprofloxacin group), G3 and G4 (two DMF groups rats treated with DMF 50mg and 100mg), and G5 and G6 (two
DMF groups rats treated with DMF 50mg and 100mg) (two ciprofloxacin Plus DMF at 50 mg and 100 mg). The tests included study of liver function, Nrf2
analysis, and anti-oxidant enzyme analysis.
Results: The serum blood Nrf2, HO-1, and tissue anti-oxidant enzymes all increased after ciprofloxacin treatment. The serum levels of Nrf2 and HO-1 were higher
in the ciprofloxacin plus DMF groups, but anti-oxidant enzymes were lower. DMF increased Nrf2 expression in rats when ciprofloxacin caused hepatotoxicity.
Conclusions: DMF lowers experimental hepatotoxicity in vivo. This effect is thought to activate the Nrf2 antioxidant defense mechanism
PRETREATMENT WITH ERYTHROPOIETIN ALLEVIATES
THE RENAL DAMAGE INDUCED BY ISCHEMIA REPERFUSION
VIA REPRESSION OF INFLAMMATORY RESPONSE
AuthorsThu-Alfeqar R. Tweij1
, Maryam A. Al-Issa2
, Manar Hamed1
, Maysaa Ali Abdul Khaleq3
, Abdullah Jasim4
, Najah R. Hadi5
Journalwiadomości lekarskie medical advances
Date2022-12-01
AbstractThe aim: This study aimed to examine the anti-inflammatory, and antiapoptotic effects of erythropoietin against kidney injury inducted by ischemia reperfusion in experimental model.
Materials and methods: 20 male Sprague Dawley rats were randomly divided into 4 equal groups: sham (subject to median laparotomy only), control (subject to 30 minutes
ischemia and 2hours reperfusion), vehicle (injected by distilled water and subjected to the same procedure of ischemia reperfusion), erythropoietin group (as in vehicle group
but the rats pretreated with 1000 U/kg of erythropoietin). The left kidney and blood specimen were collected. The blood utilized to assess serum creatinine. While kidneys utilized
to assessed MCP-1, TLR2, and caspase-3 in addition to histopathological evaluation.
Results: Control and vehicle samples showed that a significant elevation in serum creatinine, TLR2, caspase-3, and MCP-1 as compared with sham group. The histological evaluation showed a significant rise in kidney injury scores. Kidneys and blood samples of erythropoietin pretreated rats established histopathological and functional improvement
as evidenced via reduced kidney injury scores in addition to the reduction in serum creatinine, as well as there were a significant diminished in caspase-3, MCP-1, and TLR2
levels when compared with control and vehicle groups.
Conclusions: Erythropoietin has renoprotective effect against ischemia and reperfusion, which achieved by decrease the inflammatory response as well as antiapoptotic effect